Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The UK based pharmaceutical company, Ipsen has got US FDA approval for its Dysport, used in anti-wrinkle treatment. Perceived to be a rival for Botox (Allergen), its arrival is sure to intensify competition in the US aesthetics market.
Subscribe to our email newsletter
Medicis, a US based Aesthetics company, known for facial fillers like Restylane and Perlane will promote Dysport in the US as part of a sales agreement with the manufacturer. Adding Dysport to its dermal filler portfolio makes Medicis a formidable foe to Allergan – as quoted in pharmacychoice.com
Physician injectors who have used both Botox and Dysport have described that while the two are similar in many counts, they sometimes prefer one over the other in certain facial areas, due to variations in the onset of results, and spread of effect. Dysport is definitely faster-acting and has a greater and spread. While Botox has a tendency to remain more localized, requiring more injections in the course of a treatment.
Jeffrey Adelglass, Medical Director, SKINTASTIC Medical and Surgical Rejuvenation Center of Plano, said: the major benefits of Dysport(TM) to the cosmetic patient will be that there are fewer injections, and treatments hopefully will last a little longer.
Ipsen will start producing Dysport within the next 60 days. The imminent emergence of the first rival Dysport in the US coupled with news of the FDA’s strict ruling that it must have stronger product safety warnings may give Botox some cause for concern.